PURPLE BIOTECH LTD.
Business
PURPLE BIOTECH LTD. develops first-in-class oncology therapies that seek to overcome tumor immune evasion and drug resistance. Its principal product candidates and technologies include CM24 (an anti-CEACAM1 monoclonal antibody), NT219 (a dual IRS1/2 and STAT3 small molecule), and the CAPTN-3 tribody platform with lead candidate IM1240. The company operates primarily through research and development and clinical development activities and holds acquired subsidiaries and in‑licensed assets (including TyrNovo, FameWave and Immunorizon). It conducts clinical trials and development programs in the United States, Europe and Israel.
Summary from filing dated 2025-03-10
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-26.49M |
| Total assets | $17.57M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |